Treatment with a combined BRAF/MEK–targeted approach previously demonstrated success in stage III/IV melanoma, leading Columbus-AD trial investigators to evaluate encorafenib and binimetinib in stage IIB/C, BRAFV600E/K–mutated disease.
Of Interest
PD-1 Regulates CD30, Curbs T Cell Suppression in Melanoma
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors.
Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma
Cobolimab addition to dostarlimab improved major pathological response rates in high-risk resectable melanoma compared to monotherapy.
Certain Melanoma Patients With Brain Metastases May Fare Better on First-Line Targeted Therapy
NEW YORK – Patients with symptomatic melanoma brain metastases harboring BRAF V600 mutations fared better on a combination of targeted therapy and immunotherapy as a first-line treatment compared to a dual checkpoint inhibitor combo.